Quick Comparison
| Emoxypine (Mexidol) | PQQ | |
|---|---|---|
| Half-Life | 2-2.6 hours | 3-5 hours (plasma), but effects on mitochondrial biogenesis persist |
| Typical Dosage | Standard: 125-375 mg daily in 2-3 divided doses. Commonly 125 mg twice daily. Take with food. Effects are noticeable within 30-60 minutes. Russian clinical practice uses 4-6 week courses. | Standard: 10-20 mg daily. Often combined with CoQ10 (100-300 mg) for synergistic mitochondrial support. Higher doses (40 mg) are used in some research settings. |
| Administration | Oral (tablets). Also available as IV/IM injection in clinical settings. Mexidol is the brand name. | Oral (capsules, softgels). Best absorbed on an empty stomach. BioPQQ is the most studied branded form. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Emoxypine (Mexidol)
Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) has a 3-hydroxypyridine structure similar to vitamin B6 (pyridoxine). It is one of the most potent inhibitors of lipid peroxidation in brain tissue — it scavenges hydroxyl radicals and peroxyl radicals, inhibits Fe2+-induced lipid peroxidation, and may chelate transition metals. It modulates the GABA-benzodiazepine receptor complex (GABA-A), enhancing GABAergic transmission through positive allosteric modulation — possibly at a site distinct from the classical benzodiazepine binding site, explaining the lack of sedation and tolerance. It improves mitochondrial function (Complex I protection, membrane stabilization), stabilizes cell membranes (reducing fluidity changes during oxidative stress), and enhances cerebral microcirculation (possibly via nitric oxide or prostaglandin modulation). The anxiolytic mechanism may involve partial agonism or different subunit selectivity.
PQQ
PQQ activates PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master transcriptional regulator of mitochondrial biogenesis. PGC-1alpha coactivates NRF-1 and NRF-2, which drive expression of mitochondrial transcription factor A (TFAM) and nuclear-encoded mitochondrial genes—the process of creating new mitochondria in existing cells. This is unique among commercially available supplements. PQQ also provides antioxidant protection through extremely efficient redox cycling at the N5 position; it can undergo thousands of oxidation-reduction cycles before being exhausted, estimated at 5,000x the efficiency of vitamin C. PQQ activates the CREB (cAMP response element-binding protein) signaling pathway and may enhance NGF signaling, supporting BDNF expression, synaptic plasticity, and neuronal survival.
Risks & Safety
Emoxypine (Mexidol)
Common
Mild nausea, drowsiness, dry mouth.
Serious
Limited Western safety data. Allergic reactions reported.
Rare
Elevated blood pressure, emotional lability.
PQQ
Common
Very few — PQQ has an excellent safety profile at standard doses. Mild headache, fatigue initially.
Serious
No serious adverse effects documented.
Rare
Insomnia, irritability.
Full Profiles
Emoxypine (Mexidol) →
A vitamin B6 derivative with powerful antioxidant and anxiolytic properties, widely prescribed in Russia and Eastern Europe for anxiety, cognitive impairment, and cerebrovascular disease. Emoxypine inhibits lipid peroxidation, modulates GABA-A and benzodiazepine binding sites, and improves cerebral blood flow. It provides anxiolytic effects similar to benzodiazepines without sedation, tolerance, or addiction.
PQQ →
Pyrroloquinoline quinone is a redox cofactor that is the only known compound that can stimulate the growth of new mitochondria (mitochondrial biogenesis) in existing cells. Since mitochondrial density and function decline with age, PQQ addresses a root cause of age-related cognitive decline. It also provides potent antioxidant protection — estimated to be 5,000x more efficient at redox cycling than vitamin C.